Trial Profile

A Phase 2 Open-label, Single Arm Study of MK-7119 in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic HER2+ Breast Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 21 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms MK-7119-001
Sponsors Pfizer

09 Jan 2026 Planned End Date changed from 25 Nov 2025 to 30 Jun 2026.
20 Feb 2025 Planned End Date changed from 6 Dec 2028 to 25 Nov 2025.
30 Nov 2022 Planned primary completion date changed from 6 Jan 2023 to 17 Jul 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com